📊 PASG Key Takeaways
Is Passage BIO, Inc. (PASG) a Good Investment?
Passage BIO is a pre-revenue biotech company with no commercial products and significant annual cash burn of $13M. While the balance sheet is unlevered with $33.3M in cash providing approximately 2.5 years of operational runway, the company faces fundamental challenges including negative ROE (-64.3%), negative ROA (-20.7%), and persistent operating losses. Without visibility into clinical development progress or near-term revenue catalysts, the financial fundamentals reveal a high-risk entity likely requiring additional capital raises and equity dilution before achieving profitability.
Passage BIO, Inc. Key Strengths (PASG)
- Zero debt with strong balance sheet structure enabling focus on R&D
- Adequate liquidity position with $33.3M cash and 1.73x current ratio providing near-term operational stability
- Low capital intensity with minimal capex requirements reducing cash burn drag
PASG Stock Risks: Passage BIO, Inc. Investment Risks
- Pre-revenue company with no demonstrated commercial viability or revenue-generating assets
- Annual cash burn of $13M against total assets of $36.5M creates limited financial runway of approximately 2.5 years without additional funding
- Shareholder value destruction evident in -64.3% ROE and -20.7% ROA with no visibility to profitability inflection
- Imminent need for capital raise will likely result in significant dilution to existing shareholders
Key Metrics to Watch
- Quarterly cash burn rate trend and runway extension
- Clinical trial advancement stage and regulatory milestones
- Capital raise announcements and terms (dilution percentage)
Passage BIO, Inc. (PASG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Passage BIO, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
PASG Profit Margin, ROE & Profitability Analysis
PASG vs Healthcare Sector: How Passage BIO, Inc. Compares
How Passage BIO, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Passage BIO, Inc. Stock Overvalued? PASG Valuation Analysis 2026
Based on fundamental analysis, Passage BIO, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Passage BIO, Inc. Balance Sheet: PASG Debt, Cash & Liquidity
PASG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Passage BIO, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-21.04 indicates the company is currently unprofitable.
PASG Revenue Growth, EPS Growth & YoY Performance
Passage BIO, Inc. Dividends, Buybacks & Capital Allocation
PASG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Passage BIO, Inc. (CIK: 0001787297)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PASG
What is the AI rating for PASG?
Passage BIO, Inc. (PASG) has an AI grade of C with 70% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PASG's key strengths?
Claude: Zero debt with strong balance sheet structure enabling focus on R&D. Adequate liquidity position with $33.3M cash and 1.73x current ratio providing near-term operational stability.
What are the risks of investing in PASG?
Claude: Pre-revenue company with no demonstrated commercial viability or revenue-generating assets. Annual cash burn of $13M against total assets of $36.5M creates limited financial runway of approximately 2.5 years without additional funding.
What is PASG's revenue and growth?
Passage BIO, Inc. reported revenue of N/A.
Does PASG pay dividends?
Passage BIO, Inc. does not currently pay dividends.
Where can I find PASG SEC filings?
Official SEC filings for Passage BIO, Inc. (CIK: 0001787297) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PASG's EPS?
Passage BIO, Inc. has a diluted EPS of $-2.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PASG's fundamental grade?
Based on our AI fundamental analysis in May 2026, Passage BIO, Inc. has a C grade with 70% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PASG stock overvalued or undervalued?
Valuation metrics for PASG: ROE of -64.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PASG's AI grade for 2026?
Our dual AI analysis gives Passage BIO, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PASG's free cash flow?
Passage BIO, Inc.'s operating cash flow is $-13.0M, with capital expenditures of $34.0K.
How does PASG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -64.3% (avg: 15%), current ratio 1.73 (avg: 2).